Healthcare provider profile · identity verified

Catherine E Clements, M.D.

Internal Medicine · BALTIMORE, MD · NPI 1972828424

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	511	154
Amlodipine Besylate	Amlodipine Besylate	476	135
Metoprolol Succinate	Metoprolol Succinate	343	99
Losartan Potassium	Losartan Potassium	332	98
Levothyroxine Sodium	Levothyroxine Sodium	267	77
Omeprazole	Omeprazole	257	72
Hydrochlorothiazide	Hydrochlorothiazide	243	77
Lisinopril	Lisinopril	234	63
Rosuvastatin Calcium	Rosuvastatin Calcium	213	61
Pravastatin Sodium	Pravastatin Sodium	192	58
Simvastatin	Simvastatin	192	55
Gabapentin	Gabapentin	175	58
Albuterol Sulfate Hfa	Albuterol Sulfate	154	40
Famotidine	Famotidine	132	38
Furosemide	Furosemide	131	29
Trazodone Hcl	Trazodone Hcl	130	38
Sertraline Hcl	Sertraline Hcl	126	42
Alendronate Sodium	Alendronate Sodium	114	27
Escitalopram Oxalate	Escitalopram Oxalate	114	37
Pantoprazole Sodium	Pantoprazole Sodium	114	39
Ozempic	Semaglutide	107	25
Metformin Hcl	Metformin Hcl	101	36
Montelukast Sodium	Montelukast Sodium	96	27
Metformin Hcl Er	Metformin Hcl	92	32
Jardiance	Empagliflozin	82	22
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	81	23
Alprazolam	Alprazolam	76	16
Spironolactone	Spironolactone	74	21
Duloxetine Hcl	Duloxetine Hcl	68	25
Olmesartan Medoxomil	Olmesartan Medoxomil	67	19
Pregabalin	Pregabalin	62	15
Buspirone Hcl	Buspirone Hcl	61	12
Eliquis	Apixaban	60	13
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	59	suppressed
Allopurinol	Allopurinol	58	19
Doxycycline Hyclate	Doxycycline Hyclate	57	50
Fenofibrate	Fenofibrate Nanocrystallized	57	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	56	17
Synthroid	Levothyroxine Sodium	54	14
Tamsulosin Hcl	Tamsulosin Hcl	54	14
Baclofen	Baclofen	53	20
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	53	45
Metoprolol Tartrate	Metoprolol Tartrate	52	16
Fluticasone Propionate	Fluticasone Propionate	50	21
Atenolol	Atenolol	49	16
Bupropion Xl	Bupropion Hcl	49	17
Meloxicam	Meloxicam	47	17
Potassium Chloride	Potassium Chloride	47	14
Carvedilol	Carvedilol	46	11
Clopidogrel	Clopidogrel Bisulfate	46	16
Amlodipine-Olmesartan	Amlodipine Bes/Olmesartan Med	42	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	41	14
Methylprednisolone	Methylprednisolone	39	37
Venlafaxine Hcl Er	Venlafaxine Hcl	39	11
Trulicity	Dulaglutide	38	suppressed
Mounjaro	Tirzepatide	37	suppressed
Glimepiride	Glimepiride	36	suppressed
Ibuprofen	Ibuprofen	36	14
Amoxicillin	Amoxicillin	35	27
Hydralazine Hcl	Hydralazine Hcl	35	14
Azelastine Hcl	Azelastine Hcl	34	suppressed
Azithromycin	Azithromycin	34	32
Clonazepam	Clonazepam	34	suppressed
Lorazepam	Lorazepam	34	suppressed
Meclizine Hcl	Meclizine Hcl	33	18
Nifedipine Er	Nifedipine	32	suppressed
Propranolol Hcl	Propranolol Hcl	30	suppressed
Diclofenac Sodium	Diclofenac Sodium	29	suppressed
Fenofibrate	Fenofibrate	29	suppressed
Lovastatin	Lovastatin	29	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	29	suppressed
Prednisone	Prednisone	29	19
Ezetimibe	Ezetimibe	28	11
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	27	suppressed
Mirtazapine	Mirtazapine	27	suppressed
Myrbetriq	Mirabegron	27	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	27	19
Tizanidine Hcl	Tizanidine Hcl	26	suppressed
Topiramate	Topiramate	26	suppressed
Paroxetine Hcl	Paroxetine Hcl	25	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	25	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	24	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	24	suppressed
Citalopram Hbr	Citalopram Hydrobromide	23	suppressed
Benazepril Hcl	Benazepril Hcl	22	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	22	suppressed
Propranolol Hcl Er	Propranolol Hcl	22	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	21	suppressed
Ramipril	Ramipril	21	suppressed
Breo Ellipta	Fluticasone/Vilanterol	20	suppressed
Glipizide	Glipizide	20	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	20	20
Xarelto	Rivaroxaban	20	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	19	suppressed
Naproxen	Naproxen	19	suppressed
Valacyclovir	Valacyclovir Hcl	19	11
Candesartan Cilexetil	Candesartan Cilexetil	18	suppressed
Irbesartan	Irbesartan	18	suppressed
Verapamil Er	Verapamil Hcl	18	suppressed
Ketoconazole	Ketoconazole	17	suppressed
Tramadol Hcl	Tramadol Hcl	17	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	16	suppressed
Glipizide Er	Glipizide	16	suppressed
Metaxalone	Metaxalone	15	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	15	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	14	suppressed
Januvia	Sitagliptin Phosphate	14	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	14	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	14	suppressed
Arnuity Ellipta	Fluticasone Furoate	13	suppressed
Fluconazole	Fluconazole	13	suppressed
Methimazole	Methimazole	13	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	13	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	12	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Methylphenidate Er	Methylphenidate Hcl	12	suppressed
Tradjenta	Linagliptin	12	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	12	suppressed
Entresto	Sacubitril/Valsartan	11	suppressed
Lidocaine	Lidocaine	11	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	11	suppressed
Praluent Pen	Alirocumab	11	suppressed
Valsartan	Valsartan	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error